XCath, a Houston, TX-based medical device company developing neuro-endovascular surgical robotics, has raised $30 million in a Series C funding round led by Crescent Enterprises and by Dr Fred Moll.
The funding round brings the company’s total funding to $92 million.
Read More:BackOps Raises $26M Series A Funding
The company intends to use the funds to support its ongoing efforts to bring its commercially practical endovascular robot to the market and to perform a clinical telerobotic mechanical thrombectomy.
XCath is a medical device company developing robotic technology for neuro-endovascular surgery. The latest funding follows its successful first in human procedures in November 2025, where its Iris robotic system treated patients with complex brain aneurysms. The procedures were performed by Dr Vitor Mendes Pereira at The Panama Clinic in Panama City with Dr Anastasio Ameijeiras Sibauste as the local principal investigator. This marked only the second time a surgical robot has been used for an intracranial neurovascular procedure, strengthening XCath’s position in endovascular robotics.
XCath’s Iris is the only endovascular robotic system currently in development to achieve intracranial navigation or neurointerventional treatment. It is also the only robot in the world to have performed an intracranial neurovascular procedure involving the robotic manipulation of three devices, and the only system to have operated using standard monoplane imaging equipment.
“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases,” said Eduardo Fonseca Chief Executive Officer of XCath. “In 2025, the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”
“Robotic surgery succeeds when innovation is combined with practical execution,” said Dr Moll. “XCath has built a strong technology foundation and a team that values precision and experience. I’m excited to support their mission to expand global access to high-quality care for stroke patients.”
“Surgical robotics represents one of the most compelling long-term investment opportunities in healthcare. XCath has assembled an exceptional team of physicians, entrepreneurs and engineers, clearly focused on addressing a significant global healthcare unmet need,” said Neeraj Agrawal, XCath Board Member and Crescent Enterprises Executive Director.
“Treating stroke and other neurovascular diseases is one of the biggest opportunities in healthcare, driven by strong demand and supportive reimbursement,” said Nicholas Drysdale, CFO of XCath. “With continued investor support and careful use of capital, XCath is well positioned to build a leading platform in endovascular robotics.”
About XCath
Founded in 2017 by Frederic Moll, XCath is a startup developing advanced surgical robotics. The company has campuses in Houston, Texas—home to the world’s largest medical centre—and in Pangyo, South Korea, known as the “Silicon Valley of Korea.” XCath aims to bring its innovative medical solutions to patients worldwide.
Read More:Dark Watch Raises $3.5M in Seed Funding
